RxDoctor Payments Data

Warren Felton, MD

Neurology · Richmond, VANPI 1598783680

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $87,040 of the $96,206 with a category attached, or 90.5%. AstraZeneca accounts for 96.3% of it on its own, with 11 other manufacturers making up the rest. Among neurology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$96,206in general payments, 2019–2025

Across 91 payments — averaging $1057.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$93K
  • Biogen$2K
  • EMD Serono, Inc.$435
  • Amgen$427
  • Genentech USA, Inc.$357
  • Sanofi$234
  • plus $432 from 6 others
$225,721in research payments, 2019–2025

Across 75 payments — averaging $3009.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Chugai Pharmaceutical Co., Ltd.$58K
  • Roche Products Limited$55K
  • Biogen$42K
  • EMD Serono, Inc.$39K
  • Mallinckrodt Hospital Products Inc.$13K
  • Mallinckrodt Enterprises LLC$7K
  • plus $13K from 2 others

What the payments were for

  • Consulting fees$1,6132%
  • Speaking & faculty fees$87,04090%
  • Travel & lodging$3,5974%
  • Food & beverage$3,4744%
  • Education$4821%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$96,206 in reported general payments places this provider in the 90th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$46,194
Medicare patients
241
Services billed
483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex Pen (4 Pack)Interferon Beta-1a12$183,450
BetaseronInterferon Beta-1b12$135,904
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$65,081
Nurtec OdtRimegepant Sulfate11$23,830
Aimovig AutoinjectorErenumab-Aooe22$18,021
Gabapentin105$3,372
Acetazolamide ErAcetazolamide19$2,533
Baclofen50$1,213
Acetazolamide16$965
Levetiracetam12$795
Nortriptyline Hcl44$719
Tizanidine Hcl26$622
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine20$541
Topiramate32$537
Memantine Hcl22$379

Paid to pharmacies, not to this prescriber.

Other neurology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →